文献速递间质性肺疾病

纤维化相关细胞外囊泡microRNA与系统性硬化肺受累的关联

Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis.
PubMed 文献 · Eur Respir J · 2025-06-05

该研究从91例系统性硬化患者(45例合并间质性肺病、46例无间质性肺病)及43名健康对照血浆中分离小细胞外囊泡,通过小RNA测序和定量PCR鉴定出与系统性硬化相关间质性肺病相关的4-miRNA特征,其诊断曲线下面积为0.85(95%CI 0.76-0.94;p<0.0001),并与肺功能指标相关。

要点

  • 4-miRNA特征(miR-584-5p、miR-744-5p、miR-1307-3p、miR-10b-5p)与系统性硬化相关间质性肺病相关。
  • 该特征诊断间质性肺病的AUC为0.85(95%CI 0.76-0.94;p<0.0001)。
  • 候选miRNA与DLCO和FVC相关,提示可用于监测肺纤维化进展。

核心结论

  • 基于小细胞外囊泡的生物标志物方法鉴定出系统性硬化患者中间质性肺病相关的有前景的4-miRNA特征。
  • 与系统性硬化相关间质性肺病相关的小细胞外囊泡具有促纤维化特性,提示这些囊泡在系统性硬化严重程度中起重要作用。

研究设计与样本

  • 研究纳入91例特征明确的系统性硬化患者(合并间质性肺病45例、无间质性肺病46例)和43名匹配的健康受试者。
  • 从血浆中分离小细胞外囊泡,采用小RNA测序和定量逆转录PCR鉴定并验证与系统性硬化相关间质性肺病相关的小细胞外囊泡miRNA。
  • 评估了系统性硬化相关间质性肺病miRNA与临床参数的相关性,以及相关miRNA/小细胞外囊泡对纤维化的影响。

主要发现

  • 鉴定出与系统性硬化背景下间质性肺病相关的4-miRNA特征:miR-584-5p、miR-744-5p、miR-1307-3p和miR-10b-5p(AUC 0.85,95%CI 0.76-0.94;p<0.0001)。
  • 这些候选miRNA与肺功能检查(DLCO和FVC)相关。
  • 与系统性硬化相关间质性肺病相关的小细胞外囊泡miRNA与循环淋巴细胞正相关并在其中富集,提示这些免疫细胞是其细胞来源。
  • 功能研究显示,系统性硬化相关间质性肺病背景下小细胞外囊泡的功能特性改变,主要归因于促纤维化miR-584-5p转移至肺成纤维细胞。

关键数值与推荐

  • 4-miRNA特征诊断系统性硬化相关间质性肺病的AUC为0.85(95%CI 0.76-0.94;p<0.0001)。
  • 候选miRNA与DLCO和FVC相关。

临床怎么用

  • 该4-miRNA特征有望作为系统性硬化相关间质性肺病的早期生物标志物,辅助识别需要尽早启动抗纤维化治疗的患者。
  • 候选miRNA与DLCO和FVC相关,提示可用于监测系统性硬化患者的肺纤维化进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a pressing need to identify early biomarkers of lung involvement in systemic sclerosis to start antifibrotic therapy as soon as possible. We aimed to identify extracellular vesicle-derived microRNAs (miRNAs) that are differentially expressed between systemic sclerosis patients with and without interstitial lung disease, and to explore their diagnostic value and functional properties. METHODS: Small extracellular vesicles derived from plasma were isolated from 91 well-characterised patients with systemic sclerosis with (n=45) and without (n=46) interstitial lung disease and 43 matched healthy subjects. Small RNA-sequencing followed by quantitative reverse transcriptase PCR were used to identify and validate small extracellular vesicle miRNAs associated with systemic sclerosis-associated interstitial lung disease. Correlations between systemic sclerosis-associated interstitial lung disease miRNAs and clinical parameters were assessed, as well as the effect of related miRNAs/small extracellular vesicles on fibrosis. RESULTS: We identified a four-miRNA signature associated with interstitial lung disease in the context of systemic sclerosis (miR-584-5p, miR-744-5p, miR-1307-3p and miR-10b-5p) (area under the receiver operating characteristic curve 0.85, 95% CI 0.76-0.94; p<0.0001). Deeper analysis revealed a correlation of these candidates with pulmonary function tests (diffusing capacity of the lung for carbon monoxide and forced vital capacity), highlighting their use in monitoring lung fibrosis progression in systemic sclerosis patients. Furthermore, small extracellular vesicle miRNAs associated with systemic sclerosis-associated interstitial lung disease are positively correlated with and enriched in circulating lymphocytes, suggesting that these immune cells are their cellular source. Finally, functional studies highlighted altered functional properties of small extracellular vesicles in the context of systemic sclerosis-associated interstitial lung disease, mainly due to the transfer of profibrotic miR-584-5p in lung fibroblasts. CONCLUSIONS: Our small extracellular vesicle-based biomarker approach identified a promising four‑miRNA signature characteristic of interstitial lung disease in systemic sclerosis patients. Furthermore, the profibrotic properties of small extracellular vesicles associated with systemic sclerosis-associated interstitial lung disease suggest a prominent role of these vesicles in systemic sclerosis severity.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Guiot J, André B, Potjewijd J, et al. Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis. Eur Respir J. 2025. PMID: 39947668. doi:10.1183/13993003.00276-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。